MediXall Group, Inc.
MDXL · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.00 | -0.00 | -0.00 |
| FCF Yield | -408.52% | -529.85% | -576.02% | -385.95% |
| EV / EBITDA | -1.65 | -12.69 | -14.77 | -3.95 |
| Quality | ||||
| ROIC | 9.43% | 14.03% | 12.23% | 36.35% |
| Gross Margin | 57.39% | 72.39% | 57.33% | 48.77% |
| Cash Conversion Ratio | – | 0.61 | 0.63 | 0.14 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | 161.17% | 174.28% |
| Free Cash Flow Growth | -35.18% | 4.73% | -53.32% | 23.67% |
| Safety | ||||
| Net Debt / EBITDA | -1.33 | -12.54 | -14.60 | -3.90 |
| Interest Coverage | -6.54 | -3.59 | -1.70 | -2.06 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -11,515.48 | -17,743.28 | -4,834.02 | -5,248.76 |